pexels dominic rosenkranz 2422511 scaled

Evolving an Edge

European Biopharmaceutical Review, January 2011 Proof-of-concept (PoC) has become a widely used phrase in the biopharmaceutical space. Some pharma companies have gone as far as embedding the principle at the organisational level by dividing their structures into a pre-PoC part (discovery and early development) and a post-PoC part (full development). GlaxoSmithKline, Bayer Schering, Merck Serono and Roche are examples of companies that have implemented organisational variants of this approach. The goal of these re-structuring efforts was to realise more effective decision-making that would be better aligned with the nature of the R&D process and governance than the traditional division of the operating model into discovery and clinical development.

Discover Other Articles

Discover Other Articles